Clinical Trial Search

Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…

Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale

Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions

Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants

Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants

Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale

Primary: Alpha Learning Rate — .62; .43; .55; .21 Alpha Coefficient

Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Primary: Marijuana Abstinence — 0; 2 Participants

Primary: Time Line Follow Back (TLFB) for Cannabis Use — 1.921; 1.768; 1.201; 1.066 times/day of self-reported cannabis use

Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…

Primary: Cannabis Approach Bias — -8.43; 4.05; 5.43; -1.36 seconds

Primary: Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed — 78; 74 percentage of time asleep while in bed

Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars

Primary: Percentage of Urine Tests With Negative Cannabinoid Results During Treatment — 9.4; 14.0 Percentage

Primary: Change in Kessler Psychological Distress Scale (K10) Score — 6.4; 4.5 score on a scale

Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Cannabis Use — 55.89; 63.10 Percentage of use days

Primary: Enrollment Rate — 7 Participants

Primary: Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy — 2.625; 2.696; 2.609; 2.720 Institutional Units — p=0.711

Primary: Trough CBD Plasma Levels — 0; 0.7 CBD (ng/mL)

Primary: Concentrations of Glx (i.e., Glutamate + Glutamine) — 18.76; 18.57 mmol/kg — p=0.33

Primary: Continuous Abstinence Via Progressive Declines in Urine THCCOOH — NA ng/mL

Primary: Change in Marijuana Withdrawal Checklist (MWC) — 6.04; 11 score on a scale